â– LECTURE OVERVIEW: Organophosphate poisoning is a life-threatening toxidrome resulting from severe, uninhibited acetylcholinesterase inactivation that triggers massive cholinergic hyperstimulation.
â– MOLECULAR TOXICOLOGY & ACTIONS:
1. Phosphorylation of active site: Organophosphates (found in agricultural insecticides like parathion, malathion and nerve gases like sarin) bind covalently to the serine hydroxyl group of acetylcholinesterase (AChE), neutralizing the enzyme.
2. Acetylcholine Overdrive: Acetylcholine accumulates in synaptic clefts across muscarinic, nicotinic, and central nervous system synapses.
3. Cholinergic Excess (DUMBBELSS): Drives a massive cholinergic crisis: Diarrhea, Urination, Miosis, Bronchospasm/Bradycardia, Emesis, Lacrimation, Salivation, and Sweating. Nicotinic accumulation causes muscle fasciculations, muscle fatigue, flaccid paralysis (diaphragm failure), and central respiratory depression.
4. Chemical Aging: Over hours, the covalent bond undergo dealkylation ('aging'), rendering the AChE chemical blockade completely permanent and irreversible.
â– SPECIAL CLINICAL POPULATIONS & METABOLIC DEVIATIONS:
Infants display higher body water ratios and immature renal filtration capacity, whereas geriatric cohorts exhibit reduced physiologic reserves, progressive heart/renal decline, and polypharmacy interactions.
â– CLINICAL REGISTRY INSIGHTS:
Patient registry reviews depict high clinical validity in diverse populations, indicating highly correlated trends of symptom development and treatment responsiveness.
[HY-BOARD-1014]
🌟 Dynamic Clinical Key:
Management requires a rapid, dual-action antidote: Atropine (a competitive muscarinic blocker) to address life-threatening bradycardia and bronchospasm, and Pralidoxime (2-PAM), an oxime compound designed to dephosphorylate and regenerate active AChE. Crucially, Pralidoxime must be administered before AChE 'aging' occurs to be effective. Adjust weight-based dosing for pediatric cohorts and use the 'start low and go slow' approach for seniors. Assess demographic representation when applying trial results to real-world patients.